Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective vigilantly but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the last few shares of mine. The first CytoDyn post of mine, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set out all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire employment interview which I came away with a poor opinion of the business.

Irony of irony, my poor viewpoint of the business enterprise has grown steadily, though the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of the expertise and also associated intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and the very first new drug program endorsement ($five million), and also royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and many therapies, it’s this single treatments and a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple delivering presentations.

Can all this be smoke cigarettes and mirrors? That is a question I have been asking myself through the very start of my interest in this particular business. Judging by the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a classic battleground, or even some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *